European Journal of Nuclear Medicine and Molecular Imaging
-
Publication Venue For
- MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis. 42:222-230. 2015
- Synthesis and Biological Evaluation of 99mTc-Labelled Aminoethylbenzenesulfonamide Conjugate for In vivo Visualisation of Carbonic Anhydrase IX (CAIX) Expression in Tumor Hypoxia. 36:S309-S309. 2009
- Synthesis and preliminary biological evaluation of [F-18]JNJ41510417as a radioligand for positron emission tomography imaging of phosphodiesterase-10A in the brain. 36:S236-S236. 2009
- At-211-labeled trastuzumab: Evaluation of an alpha-particle emitting targeted radiotherapeutic for the treatment of breast carcinoma carcinomatous meningitis. 33:S184-S184. 2006
- At-211-labeled trastuzumab: Evaluation of an alpha-particle emitting targeted radiotherapeutic for the treatment of breast carcinoma carcinomatous meningitis. 33:S378-S378. 2006
- Chimeric murine/human IgG(2) anti-tenascin 81C6 monoclonal antibody: phase I trial in patients with malignant glioma of a construct with improved stability. 33:S194-S194. 2006
- Preclinical pharmacokinetic comparison of glucose-125I-Tyr3-octreotate with DOTA-125I-Tyr3-octreotate. 33:S307-S308. 2006
- Radioimmunotherapy of patients with malignant brain tumors: patient-specific dosing of I-131-labeled anti-tenacin antibody to achieve 44 Gy boost dose to resection cavity margins. 33:S194-S194. 2006
- Synthesis and preliminary evaluation of F-18 and C-11 labeled bi-cyclic nucleoside analogues (BCNAs) as potential PET reporter probes for imaging varicella-zoster virus thymidine kinase (VZV-tk) gene expression. 33:S175-S175. 2006
- A New Precursor for a High Yield Synthesis of[F-18]FHBG. 32:S268-S269. 2005
- A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells.. 31:1362-1370. 2004
- Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET.. 30:1620-1629. 2003
- Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis.. 29:1149-1154. 2002
- Whole-body biodistribution, radiation absorbed dose, and brain SPET imaging with [123i]5-i-A-85380 in healthy human subjects.. 29:183-190. 2002
- Anti-HER2 Single Domain Antibody 2Rs15d Labeled with F-18 Using a Residualizing Label: Preliminary Evaluation 2016
- The Prognostic Value of Mechanical Dyssynchrony by GSPECT vs Electrical Dyssnchrony by QRS in Patients with CAD and Ejection Fraction > 35% 2016
- An Anti-HER2 Nanobody Labeled with 18F Using a Residualizing Label for Assessing HER2 Status 2015
- Role of [11C]choline PET/CT in tailored Cyberknife stereotactic Therapy in patients with prostate recurrent isolated lymph node 2015
- Study for the definition of the frequency for routine analytical control in radiolabelling process 2014
- Validation of the mIBG SIOPEN Scoring Method in 2 independent High Risk Neuroblastoma Trial Populations 2014
- Laws versus Quality scheme: an opportunity to improve 2013
- Risk assessment and economic impact evaluation of the application of the Compounding of Radiopharmaceutical (PHARMEUROPA, Vol. 23, No. 4, October2011) 2013
- Radioiodinated O6-Benzylguanine Analogues Containing an Azido Function 2010
- Synthesis and preliminary biological evaluation of [F-18]JNJ41510417as a radioligand for positron emission tomography imaging of phosphodiesterase-10A in the brain 2009
- Phase 1 study of radiation dosimetry and clearance of no carrier added 131I-MIBG (ultratrace iobenguane) in 7 carcinoid and 4 pheochromocytoma patients 2007
- Synthesis and biological evaluation of C-11-labeled acyclic- and furo[2,3-d] pyrimidine derivative of bicyclic nucleoside analogs (BCNAs) for structure-brain uptake relationship study of BCNA tracers 2007
- Synthesis of Rh[16aneS4] At-211 and Ir[16aneS4] At-211 complexes - new prosthetic groups for labelling with astatine. 2007
- [I-125] iodoquine uptake in tumor cell lines with high ALDH expression 2007
- Phase I trial study of [131]I-labeled chimeric 81C6 mAb for the treatment of patients with non-Hodgkin's lymphoma 2004